Acute gastric mucosal lesions caused by acute infection of non‐HelicobacterpyloriHelicobacter: a case report

Tsukadaira, Toshihisa; Hayashi, Seiichi; Ota, Hiroyoshi; Kobayashi, Natsuko; Sekiguchi, Yasuhiro; Kodaira, Himiko; Matsumoto, Takehisa; Horiuchi, Kazuki; Negishi, Tatsuya; Kurahashi, Mari

doi:10.1111/hel.12814

Cited by 7 publications

(5 citation statements)

References 14 publications

(25 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The successful eradication of NHPH infections has recently been achieved by only proton pump inhibitor (PPI) treatment, without the need for antimicrobial agents. 41 In this study, because only an inhibitor of gastric acid secretion was administered, the infected H. suis might not have been entirely eradicated, but merely decreased to a level undetectable by PCR. Alternatively, the bacteria might have been naturally eradicated along with the disease progression.…”

Section: Discussionmentioning

confidence: 89%

Development of serological assays to identifyHelicobacter suisandHelicobacter pyloriinfections

Matsui

Rimbara²,

Suzuki

et al. 2022

Preprint

Self Cite

View full text Add to dashboard Cite

BackgroundHelicobacter suis hosted by hogs is the most-prevalent gastric non-Helicobacter pylori Helicobacter species (NHPH) found in humans with gastric diseases. However, there is no reliable method for diagnosing H. suis infection in clinical practice without gastric biopsy specimens. MethodsHelicobacter infection was diagnosed by using routine methods for detecting H. pylori infection and three other methods (PCR, culture accompanied by genomic analyses, and microscopy) for detecting NHPH and H. pylori infection using gastric biopsy specimens. Then, an ELISA was developed to detect serum anti-H. suis and anti-H. pylori antibody titers. Findings The serum specimens (n=101) were divided into specimens with (n=20) and without H. suis infection (n=81), or into specimens with (n=17) or without H. pylori infection (n=64) after excluding H. pylori infection-eradicated specimens (n=20). The cut-off values of the optical density in the ELISA were used to judge Helicobacter infections. The sensitivity and specificity were 100% and 92.5%, respectively, for identifying H. suis infection, or 88.2% and 87.5%, respectively, for identifying H. pylori infection, and these levels were considered acceptable for clinical application. We detected no other NHPH infections by PCR or culture in this study. Interpretation We developed the world′s first ELISA to simultaneously diagnose H. suis and H. pylori infection, which is available for large-scale medical examination. The eradication of H. suis was confirmed by the time-dependent decline of anti-H. suis antibody titers. Funding This work was supported by MEXT/JSPS KAKENHI (JP19H03474, JP20K08365) and AMED (JP20fk0108148, JP20fk0108133).

show abstract

Section: Discussionmentioning

confidence: 89%

Development of serological assays to identifyHelicobacter suisandHelicobacter pyloriinfections

Matsui

Rimbara²,

Suzuki

et al. 2022

Preprint

Self Cite

View full text Add to dashboard Cite

show abstract

“…NHPH causes infection in the human gastric mucosa, induces gastritis, and is associated with gastric MALT lymphoma. Although acute gastritis and acute gastric mucosal lesions (AGML) caused by NHPH have been reported in previous studies [ 10 – 12 ], most NHPH infections also cause chronic gastritis without symptoms [ 13 ]. Regarding MALT lymphoma, Stolte et al found it in seven of 202 patients with NHPH gastritis [ 3 ], and Okiyama et al found it in four of 15 patients with NHPH gastritis [ 5 ].…”

Section: Discussionmentioning

confidence: 99%

Triple-drug combination therapy versus six-month proton pump inhibitor monotherapy in non-Helicobacter pylori Helicobacter eradication, and hyperacid environment preference of Helicobacter suis: a clinical study

Tsukadaira,

Hayashi,

Ota

et al. 2024

BMC Gastroenterol

Self Cite

View full text Add to dashboard Cite

Background At present, eradication regimens for non-Helicobacter pylori Helicobacter (NHPH) have not been established yet. We investigated effectiveness of the standard triple-drug combination therapy for Helicobacter pylori eradication and of a proton pump inhibitor (PPI) monotherapy in eradication of NHPH. Methods Subjects were the patients who were diagnosed with NHPH-infected gastritis based on microscopic findings, helical-shaped organisms obviously larger than Helicobacter pylori, in the gastric mucosal specimens using Giemsa staining at Kenwakai Hospital between November 2010 and September 2021, whose NHPH species were identified by polymerase chain reaction (PCR) analysis of urease genes in endoscopically-biopsied samples, and who consented to NHPH eradication with either the triple-drug combination therapy for one week or a PPI monotherapy for six months. Six months after the completion of eradication, its result was determined with esophagogastroduodenoscopy, microscopic examination, and PCR analysis. In cases of unsuccessful eradication, a second eradication with the other therapy was suggested to the patient. Results PCR analysis detected NHPH in 38 patients: 36 as Helicobacter suis and two as Helicobacter heilmannii/Helicobacter ailurogastricus. Fourteen Helicobacter suis-infected and one Helicobacter heilmannii/Helicobacter ailurogastricus-infected patients requested eradication therapy. The triple-drug combination therapy succeeded in four of five patients, while the PPI monotherapy succeeded in five of 10 patients. Three of five patients who had been unsuccessful with the latter therapy requested the triple-drug combination therapy as the second eradication and all three were successful. In total, the triple-drug combination therapy succeeded in seven out of eight (87.5%) attempted cases, while the PPI monotherapy in five out of 10 (50%) attempted cases. Conclusions In NHPH eradication, the triple-drug combination therapy was considered to be effective to some extent and to become the first-line therapy. While, although less successful, PPI monotherapy appeared to be a potentially promising option particularly for patients with allergy or resistance to antibiotics. Effectiveness of PPI monotherapy may be attributed to hyperacid environment preference of Helicobacter suis and PPI’s acid-suppressive effect. Additionally, male predominance in NHPH-infected gastritis patients may be explained by gender difference in gastric acid secretory capacity. However, further evidence needs to be accumulated. Study registration This study was approved by the Research Ethics Committee of Kenwakai Hospital (No. 2,017,024).

show abstract

“…Human zoonosis due to NHPH infection has been associated with chronic gastritis, peptic ulcer disease, low-grade MALT lymphoma and gastric cancer. [275][276][277] 2.6.2 Chronic (long-standing) gastritis of specific aetiology is rare and usually represents the phenotypical expression of a condition involving other parts of the gastrointestinal tract. The aetiology can be due to communicable or non-communicable agents and is distinct from gastritis associated with systemic disease.…”

Section: Low-prevalence Gastritis: Preamblementioning

confidence: 99%

RE.GA.IN.: the Real-world Gastritis Initiative–updating the updates

Rugge,

Genta,

Malfertheiner

et al. 2024

Gut

View full text Add to dashboard Cite

At the end of the last century, a far-sighted ‘working party’ held in Sydney, Australia addressed the clinicopathological issues related to gastric inflammatory diseases. A few years later, an international conference held in Houston, Texas, USA critically updated the seminal Sydney classification. In line with these initiatives, Kyoto Global Consensus Report, flanked by the Maastricht-Florence conferences, added new clinical evidence to the gastritis clinicopathological puzzle.The most relevant topics related to the gastric inflammatory diseases have been addressed by the Real-world Gastritis Initiative (RE.GA.IN.), from disease definitions to the clinical diagnosis and prognosis. This paper reports the conclusions of the RE.GA.IN. consensus process, which culminated in Venice in November 2022 after more than 8 months of intense global scientific deliberations. A forum of gastritis scholars from five continents participated in the multidisciplinary RE.GA.IN. consensus. After lively debates on the most controversial aspects of the gastritis spectrum, the RE.GA.IN. Faculty amalgamated complementary knowledge to distil patient-centred, evidence-based statements to assist health professionals in their real-world clinical practice. The sections of this report focus on: the epidemiology of gastritis;Helicobacter pylorias dominant aetiology of environmental gastritis and as the most important determinant of the gastric oncogenetic field; the evolving knowledge on gastric autoimmunity; the clinicopathological relevance of gastric microbiota; the new diagnostic horizons of endoscopy; and the clinical priority of histologically reporting gastritis in terms of staging. The ultimate goal of RE.GA.IN. was and remains the promotion of further improvement in the clinical management of patients with gastritis.

show abstract

Acute gastric mucosal lesions caused by acute infection of non‐HelicobacterpyloriHelicobacter: a case report

Cited by 7 publications

References 14 publications

Development of serological assays to identifyHelicobacter suisandHelicobacter pyloriinfections

Development of serological assays to identifyHelicobacter suisandHelicobacter pyloriinfections

Triple-drug combination therapy versus six-month proton pump inhibitor monotherapy in non-Helicobacter pylori Helicobacter eradication, and hyperacid environment preference of Helicobacter suis: a clinical study

RE.GA.IN.: the Real-world Gastritis Initiative–updating the updates

Contact Info

Product

Resources

About